Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Lamorna Brown-Swigart"'
Autor:
Yiwey Shieh, Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart, Scott Huntsman, Donglei Hu, Jovia L. Nierenberg, Pooja Middha, Rachel S. Heise, Yushu Shi, Linda Kachuri, Qianqian Zhu, Song Yao, Christine B. Ambrosone, Marilyn L. Kwan, Bette J. Caan, John S. Witte, Lawrence H. Kushi, Laura van ‘T Veer, Laura J. Esserman, Elad Ziv
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling.
Externí odkaz:
https://doaj.org/article/138d8faa316e4fb8af5632688f767d95
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Nicole M. Sodir, Luca Pellegrinet, Roderik M. Kortlever, Tania Campos, Yong-Won Kwon, Shinseog Kim, Daniel Garcia, Alessandra Perfetto, Panayiotis Anastasiou, Lamorna Brown Swigart, Mark J. Arends, Trevor D. Littlewood, Gerard I. Evan
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Happloinsufficiency of Myc delays onset of cancers in mice. Here, the authors generated a mouse model of reversible cMyc hypomorphism and show that metronomic reduction of c-Myc in adult mice confers protection against cancers without side effects an
Externí odkaz:
https://doaj.org/article/f2edbfdb52b64070a843f6b7ca3e272f
Autor:
Philip Yang, MD, MSc, Neal W. Dickert, MD, PhD, Angela Haczku, MD, PhD, Christine Spainhour, RN, CCRC, Sara C. Auld, MD, MSc, the I-SPY COVID Consortium, Neil R. Aggarwal, MD, MHSc, Timothy Albertson, MD, Sara Auld, MD, Jeremy R. Beitler, MD, MPH, Paul Berger, DO, Ellen L. Burnham, MD, Carolyn S. Calfee, MD, MAS, Nathan Cobb, MD, Alessio Crippa, PhD, Andrea Discacciati, PhD, Martin Eklund, PhD, Laura Esserman, MD, MBA, D. Clark Files, MD, Eliot Friedman, MD, Sheetal Gandotra, MD, Kashif Khan, MD, Jonathan Koff, MD, Santhi Kumar, MD, Kathleen D. Liu, MD, PhD, Thomas R. Martin, MD, Michael A. Matthay, MD, Nuala J. Meyer, MD, Timothy Obermiller, MD, MS, Philip Robinson, MD, Derek Russell, MD, Karl Thomas, MD, Se Fum Wong, MD, Richard G. Wunderink, MD, Mark M. Wurfel, PhD, MD, Albert Yen, MD, Fady A. Youssef, MD, Anita Darmanian, MD, Amy L. Dzierba, PharmD, Ivan Garcia, RRT, Katarzyna Gosek, PharmD, Purnema Madahar, MD, MS, Aaron M. Mittel, MD, Justin Muir, PharmD, Amanda Roden, MD, John Schicchi, MD, Alexis L. Serra, MD, MPH, Romina Wahab, MD, Kevin W. Gibbs, MD, Leigha Landreth, RN, Mary LaRose, RN, Lisa Parks, RN, Adina Wynn, MPH, CCRP, Caroline A. G. Ittner, PhD, Nilam S. Mangalmurti, MD, John P. Reilly, MD, MS, Donna Harris, BSN, Abhishek Methukupally, MBBS, Siddharth Patel, MBBS, MPH, Lindsie Boerger, BA, John Kazianis, MD, Carrie Higgins, Jeff McKeehan, MS, Brian Daniel, RCP, RRT, Scott Fields, PharmD, James Hurst-Hopf, MS, Alejandra Jauregui, BA, Lamorna Brown Swigart, PhD, Daniel Belvins, CCRP, Catherine Nguyen, MD, Alexis Suarez, MS, Maged A. Tanios, MD, Farjad Sarafian, MD, Usman Shah, MD, Max Adelman, MD, MSc, Christina Creel-Bulos, MD, Joshua Detelich, MD, Gavin Harris, MD, Katherine Nugent, MD, Philip Yang, MD, Erin Hardy, Richart Harper, MD, Brian Morrissey, MD, Christian Sandrock, MD, MPH, G. R. Scott Budinger, MD, Helen K. Donnelly, RN, BSN, Benjamin D. Singer, MD, Ari Moskowitz, MD, Melissa Coleman, MD, Joseph Levitt, MD, Ruixiao Lu, PhD, Paul Henderson, PhD, Adam Asare, PhD, Imogene Dunn, PhD, Alejandro Botello Barragan
Publikováno v:
Critical Care Explorations, Vol 5, Iss 6, p e0930 (2023)
OBJECTIVES:. To analyze the temporal trend in enrollment rates in a COVID-19 platform trial during the first three waves of the pandemic in the United States. DESIGN:. Secondary analysis of data from the I-SPY COVID randomized controlled trial (RCT).
Externí odkaz:
https://doaj.org/article/7af4c25ca81249e2a0432daa16bb510e
Autor:
D. Clark Files, Neil Aggarwal, Timothy Albertson, Sara Auld, Jeremy R. Beitler, Paul Berger, Ellen L. Burnham, Carolyn S. Calfee, Nathan Cobb, Alessio Crippa, Andrea Discacciati, Martin Eklund, Laura Esserman, Eliot Friedman, Sheetal Gandotra, Kashif Khan, Jonathan Koff, Santhi Kumar, Kathleen D. Liu, Thomas R. Martin, Michael A. Matthay, Nuala J. Meyer, Timothy Obermiller, Philip Robinson, Derek Russell, Karl Thomas, Se Fum Wong, Richard G. Wunderink, Mark M. Wurfel, Albert Yen, Fady A. Youssef, Anita Darmanian, Amy L. Dzierba, Ivan Garcia, Katarzyna Gosek, Purnema Madahar, Aaron M. Mittel, Justin Muir, Amanda Rosen, John Schicchi, Alexis L. Serra, Romina Wahab, Kevin W. Gibbs, Leigha Landreth, Mary LaRose, Lisa Parks, Adina Wynn, Caroline A.G. Ittner, Nilman S. Mangalmurti, John P. Reilly, Donna Harris, Abhishek Methukupally, Siddharth Patel, Lindsie Boerger, John Kazianis, Carrie Higgins, Jeff McKeehan, Brian Daniel, Scott Fields, James Hurst-Hopf, Alejandra Jauregui, Lamorna Brown Swigart, Daniel Blevins, Catherine Nguyen, Alexis Suarez, Maged A. Tanios, Farjad Sarafian, Usman Shah, Max Adelman, Christina Creel-Bulos, Joshua Detelich, Gavin Harris, Katherine Nugent, Christina Spainhour, Philip Yang, Angela Haczku, Erin Hardy, Richart Harper, Brian Morrissey, Christian Sandrock, G. R. Scott Budinger, Helen K. Donnelly, Benjamin D. Singer, Ari Moskowitz, Melissa Coleman, Joseph Levitt, Ruixiao Lu, Paul Henderson, Adam Asare, Imogene Dunn, Alejandro Botello Barragan
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101889- (2023)
Summary: Background: An urgent need exists to rapidly screen potential therapeutics for severe COVID-19 or other emerging pathogens associated with high morbidity and mortality. Methods: Using an adaptive platform design created to rapidly evaluate i
Externí odkaz:
https://doaj.org/article/455f6804c6664df29b7f69d1279558b0
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Mark Jesus M. Magbanua, Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart, David C. Newitt, Jessica Gibbs, Amy L. Delson, Ekaterina Kalashnikova, Alexey Aleshin, Bernhard Zimmermann, A. Jo Chien, Debu Tripathy, Laura Esserman, Nola Hylton, Laura van ‘t Veer
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract We investigated whether serial measurements of circulating tumor DNA (ctDNA) and functional tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve prediction of pathologic complete response (pCR) and estimation of
Externí odkaz:
https://doaj.org/article/fc14e93945954cfb88f54bbbdcc007fe
Autor:
Mark Jesus M. Magbanua, Laura van ‘t Veer, Amy S. Clark, A. Jo Chien, Judy C. Boughey, Hyo S. Han, Anne Wallace, Heather Beckwith, Minetta C. Liu, Christina Yau, E. Paul Wileyto, Andrea Ordonez, Tulasi I. Solanki, Feng Hsiao, Jen Chieh Lee, Amrita Basu, Lamorna Brown Swigart, Jane Perlmutter, Amy L. Delson, Lauren Bayne, Shannon Deluca, Stephanie S. Yee, Erica L. Carpenter, Laura J. Esserman, John W. Park, Lewis A. Chodosh, Angela DeMichele
Publikováno v:
Breast Cancer Research and Treatment. 198:383-390
Autor:
A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman
Publikováno v:
Cancer Research. 82:OT1-10
Background: There is no clinical equipoise on the best upfront management of patients with early-stage hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer (BC) that is high-risk by clinicopathologic criteria, and low-risk based on mol